Most of which is opinion stated as fact. Most of these drugs wouldn't even bother releasing 25 day data on 14 people I would imagine. I have little doubt the FDA will allow a P3 however. It's not really their job to grant P3s, just to make sure they are safe when the are signed off on. Certainly not saying there isn't possible a positive signal in ONE data point measured but IMO its way overvalued at this point. There were 5 possible endpoints and the company provides data on ONE and that one didn't meet the endpoint either unless you compare to baseline. From the clinical trial website. https://www.clinicaltrials.gov/ct2/show/NCT04524351
Even SNPX has positive data for 13 weeks and that still isn't enough to weed out potential placebo effects and the trial was for over 100 patients with a P value way better than ANVS when comparing baseline scores.
News 
Market Data 
Discover 
